Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1/2 6Phase 3 5Phase 1 4Phase NA 2Phase EARLY_PHASE1 1

Status

Recruiting 3Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 1HER2 IHC3+ Advanced Colorectal Cancer 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × tipiracil × Clear all
NCT07549412 2026-05-08

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

EMD Serono

Phase 3 Recruiting
1,020 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07483684 2026-03-19

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
142 enrolled
Gastrointestinal

HER2 IHC3+ Advanced Colorectal Cancer

NCT04776148 2026-02-05

MK-7902-017

Merck Sharp & Dohme LLC

Phase 3 Completed
563 enrolled 32 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT07361003 2026-01-22

A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3 Recruiting
464 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06992648 2025-05-28

REGTAS-2

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3 Recruiting
302 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡